52
Participants
Start Date
June 30, 2007
Primary Completion Date
October 31, 2012
Study Completion Date
October 31, 2012
Dasatinib
Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression
Capecitabine
Tablets, Oral, 660 - 1250 mg/m\^2 twice a day (BID). Treatment may continue until disease progression.
New York Presbyterian Hospital, New York
Local Institution, Rozzano
Local Institution, Seville
Northwestern University Feinberg School Of Medicine, Chicago
City Of Hope National Medical Center, Duarte
Seattle Cancer Care Alliance, Seattle
Local Institution, Barcelona
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY